论文部分内容阅读
目的探讨氨基胍(AG)对糖尿病大鼠肾脏中糖基化终末产物(AGEs)和脂质过氧化物(LPO)的影响。方法将36只雄性SD大鼠随机分为正常对照组(N组)、模型组(DM组)和AG组,用链脲佐菌素制作糖尿病大鼠模型。AG组给予AG治疗8周。测定各组大鼠肾质量/体质量、血尿素氮(BUN)、血肌酐(SCr)2、4 h尿蛋白定量、肾小球AGEs(GTE-AGEs)、血清和尿中抗CML-AGEs及LMN-AGEs、肾小球和血清LPO含量,观察肾脏病理改变。结果DM组大鼠血清BUN、SCr、血清AGEs、血清LPO、GTE-AGEs、GTE-LPO、肾质量/体质量、24 h尿蛋白定量均显著高于N组,AG组血清BUN、血清SCr、血清CML-AGEs、血清LPO、GTE-AGEs、GTE-LPO、肾质量/体质量、24 h尿蛋白定量均显著低于N组,尿中AGEs、血清CML-AGE含量显著高于DM组和N组;AG可显著减轻肾脏病理学改变。结论氨基胍可通过减少AGEs在糖尿病大鼠肾脏的蓄积,降低尿蛋白排泄,减少氧化应激水平及其他间接作用,发挥其对糖尿病肾病的防治作用。
Objective To investigate the effects of aminoguanidine (AG) on advanced glycation end products (AGEs) and lipid peroxides (LPO) in diabetic rats. Methods Thirty-six male Sprague-Dawley rats were randomly divided into normal control group (N group), model group (DM group) and AG group. Diabetic rats were induced by streptozotocin. AG group given AG for 8 weeks. The renal mass, body mass, blood urea nitrogen (BUN), serum creatinine (SCr) 2,4 urinary protein, glomerular AGEs (GTE-AGEs), anti-CML- LMN-AGEs, glomerular and serum LPO levels were observed renal pathological changes. Results Serum levels of BUN, SCr, serum AGEs, serum LPO, GTE-AGEs, GTE-LPO, kidney mass / body weight and 24 h urinary protein in DM group were significantly higher than those in N group. Serum BUN, The levels of serum CML-AGEs, serum LPO, GTE-AGEs, GTE-LPO, kidney mass / body weight and 24 h urinary protein were all significantly lower than those in group N Group; AG can significantly reduce renal pathological changes. Conclusion Aminoguanidine can exert its preventive and therapeutic effects on diabetic nephropathy by reducing AGEs accumulation in the kidney of diabetic rats, decreasing urinary protein excretion, reducing oxidative stress and other indirect effects.